Abstract
ABSTRACT Rhodopsin misfolding underlies rhodopsin-linked retinitis pigmentosa, and small-molecule pharmacochaperones represent a promising therapeutic strategy. However, the mechanisms by which these compounds interact with and stabilize rhodopsin remain poorly understood. Here, we combine backbone amide hydrogen-deuterium exchange mass spectrometry (amide HDX-MS), histidine-specific HDX (His-HDX), protein structure network (PSN) analysis, molecular docking, and functional spectroscopy to define ligand-induced conformational signatures in this receptor elicited by three non-retinoid small molecules, quercetin, myricetin, and the chromenone CR5, and to compare them with those of the native chromophore 11- cis -retinal. Binding of 11- cis -retinal to ligand-free opsin establishes a benchmark orthosteric conformational signature, characterized by strong backbone HDX protection across TM4-TM7 and adjacent loops, suppression of EX1-like hydrogen-deuterium exchange kinetics at the N-terminal ends of TM1 and TM4, and reorganization of PSN hubs that stabilizes an inactive-state residue interaction network. All three non-retinoid ligands generate HDX footprints that closely track this retinal-induced pattern within the chromophore pocket, consistent with direct orthosteric engagement, but they confer weaker and ligand-specific stabilization. Among them, quercetin most closely reproduces the retinal-like backbone protection and His-HDX microenvironment changes, whereas myricetin and CR5 only partially recapitulate retinal-induced stabilization and redistribute conformational flexibility toward TM1 and intradiscal regions, without fully suppressing EX1-like gating. In addition, all three compounds induce weak cytoplasmic allosteric effects in retinal-bound rhodopsin, indicating secondary interactions in addition to a primary orthosteric mechanism. Together, these results provide the first residue-level experimental framework for understanding the differential pharmacochaperoning capacity of non-retinoid ligands and highlight key conformational principles for future optimization of opsin stabilizers.
Full text
2,303 characters
· extracted from
oa-html
· click to expand
ABSTRACT
Rhodopsin misfolding underlies rhodopsin-linked retinitis pigmentosa, and small-molecule pharmacochaperones represent a promising therapeutic strategy. However, the mechanisms by which these compounds interact with and stabilize rhodopsin remain poorly understood. Here, we combine backbone amide hydrogen-deuterium exchange mass spectrometry (amide HDX-MS), histidine-specific HDX (His-HDX), protein structure network (PSN) analysis, molecular docking, and functional spectroscopy to define ligand-induced conformational signatures in this receptor elicited by three non-retinoid small molecules, quercetin, myricetin, and the chromenone CR5, and to compare them with those of the native chromophore 11- cis -retinal. Binding of 11- cis -retinal to ligand-free opsin establishes a benchmark orthosteric conformational signature, characterized by strong backbone HDX protection across TM4-TM7 and adjacent loops, suppression of EX1-like hydrogen-deuterium exchange kinetics at the N-terminal ends of TM1 and TM4, and reorganization of PSN hubs that stabilizes an inactive-state residue interaction network. All three non-retinoid ligands generate HDX footprints that closely track this retinal-induced pattern within the chromophore pocket, consistent with direct orthosteric engagement, but they confer weaker and ligand-specific stabilization. Among them, quercetin most closely reproduces the retinal-like backbone protection and His-HDX microenvironment changes, whereas myricetin and CR5 only partially recapitulate retinal-induced stabilization and redistribute conformational flexibility toward TM1 and intradiscal regions, without fully suppressing EX1-like gating. In addition, all three compounds induce weak cytoplasmic allosteric effects in retinal-bound rhodopsin, indicating secondary interactions in addition to a primary orthosteric mechanism. Together, these results provide the first residue-level experimental framework for understanding the differential pharmacochaperoning capacity of non-retinoid ligands and highlight key conformational principles for future optimization of opsin stabilizers.
Full Text Availability
The license terms selected by the author(s) for this preprint version do not permit archiving in PMC. The full text is available from the preprint server.
Text is read by the "Ask this paper" AI Q&A widget below.
Extraction quality varies by source — PMC NXML preserves structure
cleanly, OA-HTML may include some navigation residue, and OA-PDF can
have broken hyphenation. The publisher copy
(via DOI)
is the canonical version.